Julia Fransson

Julia Fransson is an accomplished professional with extensive experience in the life sciences and biotechnology sectors. Currently serving as Chief Operating Officer at Atley Solutions since February 2025, Julia is focused on the production of At-211 radiopharmaceuticals for Targeted Alpha Therapy. Julia's previous roles include Director of Business Development at Cereno Scientific, CEO at MS&C Nordics, and Acting CEO at Build-r, with a strong emphasis on strategy and communication for biotech companies. Julia has also contributed to business development at iliod therapeutics and Forward Technologies AB, where responsibilities included venture management and market entry strategies. Julia holds a Master’s degree in Entrepreneurship and Business Design from Chalmers University of Technology and a Bachelor’s degree in Biotechnology from the same institution, enhancing a robust foundation in both technical and business arenas.